ASCLF
Price:
$0.1753
Market Cap:
$1.25B
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for no...[Read more]
Industry
Biotechnology
IPO Date
2019-11-19
Stock Exchange
PNK
Ticker
ASCLF
According to Ascletis Pharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.84. This represents a change of 7.12% compared to the average of -5.45 of the last 4 quarters.
The mean historical PE Ratio of Ascletis Pharma Inc. over the last ten years is -101.25. The current -5.84 PE Ratio has changed 476.78% with respect to the historical average. Over the past ten years (40 quarters), ASCLF's PE Ratio was at its highest in in the June 2018 quarter at 31.05. The PE Ratio was at its lowest in in the March 2018 quarter at -1228.99.
Average
-101.25
Median
-20.97
Minimum
-493.94
Maximum
-0.17
Discovering the peaks and valleys of Ascletis Pharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 6.42%
Maximum Annual PE Ratio = -0.17
Minimum Annual Increase = -98.25%
Minimum Annual PE Ratio = -493.94
Year | PE Ratio | Change |
---|---|---|
2023 | -8.86 | -21.20% |
2022 | -11.24 | 6.42% |
2021 | -0.17 | -98.25% |
2020 | -9.84 | -67.93% |
2019 | -30.69 | -93.79% |
2018 | -493.94 | 508.95% |
2017 | -81.11 | -53.42% |
The current PE Ratio of Ascletis Pharma Inc. (ASCLF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.76
5-year avg
-12.16
10-year avg
-101.25
Ascletis Pharma Inc.’s PE Ratio is less than Adynxx, Inc. (0), less than BioCardia, Inc. (0), less than Adial Pharmaceuticals, Inc. WT EXP 073123 (-0.83), less than null (-0.45),
Company | PE Ratio | Market cap |
---|---|---|
0 | $581.00 | |
0 | $10.12K | |
-0.83 | $0 | |
-0.45 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascletis Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascletis Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ascletis Pharma Inc.'s PE Ratio?
How is the PE Ratio calculated for Ascletis Pharma Inc. (ASCLF)?
What is the highest PE Ratio for Ascletis Pharma Inc. (ASCLF)?
What is the 3-year average PE Ratio for Ascletis Pharma Inc. (ASCLF)?
What is the 5-year average PE Ratio for Ascletis Pharma Inc. (ASCLF)?
How does the current PE Ratio for Ascletis Pharma Inc. (ASCLF) compare to its historical average?